Esomeprazole – S-isomer of omeprazole with more favorable pharmacological properties and stronger pharmacodynamic effect
Drug profileGastroent Hepatol 2018; 72(2): 179–181. doi:10.14735/amgh2018179
Literaturepdf Milan LukášTreatment of an adenoma of the ascending colon with the non-lifting sign via a combination of endoscopic mucosal resection and full- thickness resection
Case reportGastroent Hepatol 2018; 72(2): 148–151. doi:10.14735/amgh2018csgh.info03
SummaryLiteraturepdf Přemysl FaltA comparison of cost-effectiveness analysis of two strategies – immediate and delayed initiation of treatment of hepatitis C in the Czech Republic
Original articleGastroent Hepatol 2018; 72(1): 58–65. doi:10.14735/amgh201858
SummaryLiteraturepdf Jana Skoupá, Petr UrbánekCan we increase the e ffectiveness of anti-TNF therapy?
EditorialGastroent Hepatol 2018; 72(1): 6–7.
Literaturepdf Martin BortlíkEndosonographically-guided drainage of pancreatic collections – personal experience
Original articleGastroent Hepatol 2017; 71(5): 401–408. doi:10.14735/amgh2017401
SummaryLiteraturepdf Karel Poc, Peter Mačinga, Petr Štirand, Pavel Wohl, Pavel Drastich, Jan Martínek, Pavel Taimr, Vladimír Nosek, Julius Špičák, Tomáš HuclRemsima® – the first biosimilar infliximab CT-P13
Drug profileGastroent Hepatol 2017; 71(4): 363–364. doi:10.14735/amgh2017363
Literaturepdf Milan LukášPotential use of non-invasive methods for non-alcoholic fatty liver disease
Review articleGastroent Hepatol 2017; 71(4): 325–332. doi:10.14735/amgh2017325
SummaryLiteraturepdf Michaela Fedelešová, Viera Kupčová, Mária Szántová, Jozef Bulas, Ladislav TureckýComment on article Biosimilar infliximab in anti-TNF naïve IBD patients – 1-year clinical follow-up
CommentGastroent Hepatol 2017; 71(4): 323–324. doi:10.14735/amgh2017323
Literaturepdf Peter D. R. HigginsGraft-duodenal fistula – a cause of massive gastrointestinal bleeding
Case reportGastroent Hepatol 2017; 71(4): 310–314. doi:10.14735/amgh2017310
SummaryLiteraturepdf Jaroslav Maceček, Bedřich Staňka, Jiří Šťastný